Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by MineDiggeron Apr 19, 2022 6:14am
224 Views
Post# 34612340

RE:RE:Updated Corporate Presentation - April 2022

RE:RE:Updated Corporate Presentation - April 2022
Using the free online comparator draftable.com and the September 2021 CP as the reference the main changes seen in their side-by-side comparison are:
No Pipeline summary Slide 4
No Patnering Slide 6
No Superior to Transferrin Slide 9 but is replaced with a different chart
No Chiesi Slide 13
... and through to 19 missing too

New Slide 14 lists Patent Protection
New Slide 15 lists Opportunity Summary

No Delivery of Antibody Targeting Beta-amyloid Slide 24

OK, I give up, too many to list. Just possible some deleted slides have been moved to later

Draftable provides a "combined" pdf you can download, but it is a bit awkward.
There seem to be a few other free online comparators available.

MD
<< Previous
Bullboard Posts
Next >>